See more : Sylvania Platinum Limited (SAPLF) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Scientific Inc. (MLSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Scientific Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Fullshare Holdings Limited (0607.HK) Income Statement Analysis – Financial Results
- PT Panca Global Kapital Tbk (PEGE.JK) Income Statement Analysis – Financial Results
- Goldhills Holding Ltd. (GODZF) Income Statement Analysis – Financial Results
- North Atlantic Acquisition Corporation (NAAC) Income Statement Analysis – Financial Results
- C’bon Cosmetics Co.,Ltd. (4926.T) Income Statement Analysis – Financial Results
Milestone Scientific Inc. (MLSS)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.milestonescientific.com
About Milestone Scientific Inc.
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | 9.62M | 11.28M | 10.48M | 9.49M | 10.33M | 10.01M | 8.65M | 8.38M | 9.75M | 8.55M | 6.62M | 6.39M | 5.84M | 6.43M | 4.75M | 3.97M | 4.07M | 4.09M | 5.67M | 2.86M | 8.80M | 2.90M | 300.00K |
| Cost of Revenue | 3.03M | 3.91M | 3.99M | 1.82M | 2.66M | 5.19M | 4.31M | 4.18M | 3.05M | 3.63M | 3.20M | 3.06M | 3.02M | 3.53M | 3.46M | 2.68M | 2.90M | 3.04M | 2.52M | 2.42M | 2.00M | 1.98M | 1.97M | 2.91M | 839.46K | 9.60M | 1.60M | 0.00 |
| Gross Profit | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | 4.43M | 6.97M | 6.31M | 6.44M | 6.70M | 6.81M | 5.59M | 5.36M | 6.22M | 5.09M | 3.94M | 3.49M | 2.81M | 3.91M | 2.34M | 1.97M | 2.09M | 2.12M | 2.77M | 2.02M | -800.00K | 1.30M | 300.00K |
| Gross Profit Ratio | 69.12% | 55.65% | 61.25% | 66.60% | 68.28% | 46.05% | 61.77% | 60.16% | 67.88% | 64.86% | 68.05% | 64.66% | 63.99% | 63.78% | 59.55% | 59.52% | 54.65% | 48.06% | 60.81% | 49.15% | 49.56% | 51.38% | 51.80% | 48.75% | 70.60% | -9.09% | 44.83% | 100.00% |
| Research & Development | 701.38K | 1.15M | 878.21K | 307.85K | 189.92K | 245.64K | 272.75K | 1.27M | 100.86K | 88.24K | 191.35K | 181.98K | 140.05K | 270.49K | 241.32K | 168.52K | 397.35K | 1.01M | 286.26K | 187.99K | 131.02K | 147.71K | 49.94K | 386.25K | 455.33K | 400.00K | 1.00M | 200.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.14M | 12.51M | 12.74M | 10.77M | 9.53M | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Other Expenses | 61.91K | 63.76K | 73.84K | -24.79K | -10.41K | -7.23K | -4.93K | -5.09K | -5.35K | 0.00 | 17.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 26.07K | 0.00 | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| Operating Expenses | 13.90M | 13.73M | 13.69M | 11.07M | 9.72M | 10.89M | 12.20M | 12.82M | 9.50M | 7.49M | 5.73M | 6.11M | 6.59M | 6.92M | 7.19M | 5.67M | 6.73M | 6.33M | 7.08M | 5.34M | 3.70M | 3.76M | 5.32M | 9.60M | 8.20M | 10.20M | 9.00M | 2.60M |
| Cost & Expenses | 16.93M | 17.63M | 17.68M | 12.89M | 12.37M | 16.08M | 16.52M | 17.00M | 12.55M | 11.12M | 8.92M | 9.17M | 9.60M | 10.45M | 10.65M | 8.35M | 9.63M | 9.37M | 9.60M | 7.76M | 5.70M | 5.74M | 7.29M | 12.51M | 9.04M | 19.80M | 10.60M | 2.60M |
| Interest Income | 0.00 | 54.61K | 16.36K | 6.71K | 1.54K | 7.45K | 9.30K | 1.29K | 3.84K | 5.06K | 115.00 | 34.00 | 35.00 | 587.00 | 3.15K | 9.02K | 0.00 | 87.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 54.61K | 16.36K | 18.08K | 0.00 | 0.00 | 0.00 | 1.29K | 0.00 | 2.67K | 70.80K | 178.97K | 131.84K | 95.14K | 154.03K | 116.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 150.77K | 144.38K | 128.93K | 130.28K | 256.47K | 881.29K | 573.15K | 163.37K | 97.38K | 95.84K | 96.12K | 95.13K | 105.39K | 128.64K | 126.39K | 127.24K | 148.91K | 118.76K | 118.15K | 101.92K | 335.22K | 417.99K | 435.18K | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| EBITDA | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | -5.58M | -4.66M | -6.35M | -2.96M | -694.34K | 1.18M | -596.20K | -1.24M | -572.20K | -2.10M | -1.73M | -3.24M | -3.52M | -3.13M | -2.91M | -1.40M | -1.25M | -2.77M | -6.12M | -5.45M | -10.50M | -7.20M | -2.10M |
| EBITDA Ratio | -70.78% | -98.61% | -70.89% | -135.31% | -1.28% | -41.97% | -41.32% | -60.59% | -31.18% | -15.48% | 2.68% | -6.89% | -11.83% | -7.72% | -22.50% | -33.97% | -53.23% | -63.09% | -62.63% | -61.17% | -35.17% | -32.04% | -69.12% | -103.48% | -162.54% | -123.86% | -262.07% | -766.67% |
| Operating Income | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | -8.00M | -5.23M | -6.51M | -3.06M | -790.18K | 1.09M | -520.35K | -1.22M | -700.84K | -2.10M | -1.73M | -3.24M | -3.52M | -3.25M | -3.01M | -1.73M | -1.67M | -3.20M | -6.84M | -6.18M | -11.00M | -7.70M | -2.30M |
| Operating Income Ratio | -72.31% | -100.24% | -71.60% | -137.08% | -47.75% | -83.14% | -46.40% | -62.14% | -32.20% | -7.65% | 10.85% | -6.02% | -14.60% | -7.19% | -24.61% | -26.10% | -50.70% | -60.28% | -50.47% | -63.31% | -43.61% | -40.98% | -78.18% | -120.48% | -216.49% | -125.00% | -265.52% | -766.67% |
| Total Other Income/Expenses | 125.53K | 54.61K | 259.82K | -18.08K | -3.64M | 215.00 | 4.37K | -3.80K | -1.51K | -907.81K | 378.23K | -349.95K | -258.50K | 86.33K | 573.43K | 541.13K | 301.55K | 370.52K | 492.87K | 11.34K | 0.00 | 53.93K | 64.49K | -246.28K | -807.60K | 400.00K | 0.00 | 200.00K |
| Income Before Tax | -6.98M | -8.77M | -7.12M | -7.47M | -7.64M | -8.00M | -5.23M | -6.52M | -3.06M | -1.70M | 1.46M | -870.31K | -1.35M | -519.96K | -2.16M | -1.08M | -2.94M | -3.15M | -2.27M | 0.00 | 0.00 | -1.62M | -3.14M | -7.08M | -6.99M | -10.60M | -7.50M | -2.10M |
| Income Before Tax Ratio | -71.04% | -99.62% | -69.08% | -137.41% | -91.27% | -83.13% | -46.36% | -62.18% | -32.22% | -16.43% | 14.63% | -10.06% | -16.12% | -5.33% | -25.23% | -16.31% | -45.98% | -53.94% | -35.26% | 0.00% | 0.00% | -39.66% | -76.60% | -124.82% | -244.77% | -120.45% | -258.62% | -700.00% |
| Income Tax Expense | 0.00 | -66.74K | 333.00 | 15.50K | 18.13K | 23.99K | 19.09K | -19.10K | 36.16K | 9.51K | -843.94K | 7.95K | 258.50K | -86.33K | -573.43K | -541.13K | -301.55K | -370.52K | -413.94K | -11.34K | 680.86K | 770.64K | 791.16K | 673.22K | 790.58K | -300.00K | -300.00K | -400.00K |
| Net Income | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M | -7.43M | -5.19M | -5.95M | -5.47M | -1.70M | 1.46M | -870.31K | -1.48M | -614.51K | -1.53M | -1.19M | -2.94M | -3.15M | -2.75M | -3.00M | -2.41M | -2.44M | -3.99M | -7.51M | -6.97M | -10.70M | -7.40M | -1.90M |
| Net Income Ratio | -70.51% | -98.87% | -69.09% | -137.69% | -91.49% | -77.24% | -45.97% | -56.73% | -57.60% | -16.47% | 14.63% | -10.06% | -17.69% | -6.30% | -17.90% | -17.93% | -45.98% | -53.94% | -42.81% | -63.08% | -60.75% | -59.90% | -97.51% | -132.35% | -244.17% | -121.59% | -255.17% | -633.33% |
| EPS | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.09 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| EPS Diluted | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| Weighted Avg Shares Out | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.03M | 20.06M | 17.13M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
| Weighted Avg Shares Out (Dil) | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.43M | 20.06M | 17.48M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call
ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time...
Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians
Follows successful evaluation by Omaha Pain Physicians' founder and medical director, Dr. Matthew Stottle, reporting 100% success Follows successful evaluation by Omaha Pain Physicians' founder and medical director, Dr. Matthew Stottle, reporting 100% success
Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio
ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System®...
Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast
ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA)...
Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update
Reports initial reimbursements of CompuFlo® by commercial payors and Medicare Reports initial reimbursements of CompuFlo® by commercial payors and Medicare
PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)
New York, December 27, 2023 – Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133...
Milestone Scientific Inc. Announces Closing of $3.0 Million Public Offering of Common Stock
ROSELAND, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of its previously announced underwritten public offering of 4,765,000 shares of...
Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock
ROSELAND, N.J., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the pricing of an underwritten public offering of 4,765,000 shares of its common stock...
Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock
ROSELAND, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock...
Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures
Adoption of the technology at UTMB Health Clear Lake Campus Hospital follows successful evaluation process in these procedures—reporting 100% success
Source: https://incomestatements.info
Category: Stock Reports